Nektar enters quiet period ahead of Phase 2b REZOLVE-AD maintenance data; data expected in February 2026

NEKTAR THERAPEUTICS

Quiet period begins January 27, 2026 and continues until public announcement of the maintenance data.
Maintenance Data are from the 36-week maintenance period of the Phase 2b REZOLVE-AD study of rezpegaldesleukin.
Next investor communication planned for February 2026 at the time of data presentation.
This quiet period is consistent with prior quiet periods for REZOLVE studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.